Serum CA19-9 is a Significant Predictor among Preoperative Parameters for Early Recurrence after Resection of Pancreatic Adenocarcinoma

被引:124
|
作者
Sugiura, Teiichi [1 ]
Uesaka, Katsuhiko [1 ]
Kanemoto, Hideyuki [1 ]
Mizuno, Takashi [1 ]
Sasaki, Keiko [2 ]
Furukawa, Hiroyoshi [3 ]
Matsunaga, Kazuya [1 ]
Maeda, Atsuyuki [1 ]
机构
[1] Shizuoka Canc Ctr, Div Hepatobiliary Pancreat Surg, Shizuoka 4118777, Japan
[2] Shizuoka Canc Ctr, Div Pathol, Shizuoka 4118777, Japan
[3] Shizuoka Canc Ctr, Div Diagnost Radiol, Shizuoka 4118777, Japan
关键词
Pancreatic cancer; CA19-9; Early recurrence; GEMCITABINE-BASED CHEMORADIATION; COMPUTED-TOMOGRAPHY; RESECTABLE ADENOCARCINOMA; BILIARY DRAINAGE; TUMOR-MARKER; CA-19-9; SURVIVAL; CHEMOTHERAPY; CANCER; THERAPY;
D O I
10.1007/s11605-012-1859-9
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
To evaluate the preoperative factors predictive of postoperative early recurrence in patients with resected pancreatic cancer focusing on the serum CA19-9 value. One hundred fifty-four patients undergoing surgical resection for pancreatic cancer were enrolled in this study. Univariate and multivariate analyses were performed to determine the predictors of early recurrence which was defined as relapse within 6 months after surgery. On ROC curve analysis, the cutoff value of CA19-9 was determined to be 100 U/ml. Of 73 patients with CA19-9 value a parts per thousand yenaEuro parts per thousand 100 U/ml, 39 (53 %) had early recurrence. In contrast, only 9 of 81 patients (11 %) with CA19-9 value < 100 U/ml developed a recurrence at an early period (p < 0.001). Multivariate analysis revealed that CA19-9 value a parts per thousand yenaEuro parts per thousand 100 U/ml (odds ratio, 11.2) were significant predictors of early recurrence. The overall 3- and 5-year survival rates and median survival times were 47.3 %, 40.1 %, and 31 months in patients with CA19-9 value < 100 U/ml and 21.2 %, 9.4 %, and 16 months in patients with CA19-9 value a parts per thousand yenaEuro parts per thousand 100 U/ml (p < 0.001). A preoperative CA19-9 value a parts per thousand yenaEuro parts per thousand 100 U/ml was a significant predictor of early recurrence and a poor prognosis after resection for pancreatic adenocarcinoma.
引用
收藏
页码:977 / 985
页数:9
相关论文
共 50 条
  • [31] CA19-9 capability as predictor of pancreatic cancer resectability in a Spanish cohort
    Marta Herreros-Villanueva
    Lourdes Ruiz-Rebollo
    Mario Montes
    Mario Rodriguez-Lopez
    María Francisco
    Joaquín Cubiella
    Eduardo Iyo
    Emilio Garabitos
    Emma Martínez Moneo
    Maider Martos
    Enrique de Madaria
    Ibon Martínez-Arránz
    Marta García-Cougil
    Agueda Iglesias-Gómez
    Luis Bujanda
    Molecular Biology Reports, 2020, 47 : 1583 - 1588
  • [32] CA19-9 as a Predictor of Resectability in Patients with Borderline Resectable Pancreatic Cancer
    He, Zhaopeng
    Lu, Huimin
    Du, Xiaojiong
    Hu, Weiming
    Tian, Bole
    Zhang, Zhaoda
    HEPATO-GASTROENTEROLOGY, 2013, 60 (124) : 900 - 903
  • [33] Clinical Utility of the Combined Use of CA19-9 and DUPAN-2 in Pancreatic Adenocarcinoma
    Sumiyoshi, Tatsuaki
    Uemura, Kenichiro
    Shintakuya, Ryuta
    Okada, Kenjiro
    Baba, Kenta
    Harada, Takumi
    Serikawa, Masahiro
    Ishii, Yasutaka
    Nakamura, Shinya
    Arihiro, Koji
    Murakami, Yoshiaki
    Takahashi, Shinya
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (07) : 4665 - 4672
  • [34] Postradiotherapy CA19-9 Kinetics Correlate With Outcomes in Patients With Pancreatic Adenocarcinoma
    Shultz, David B.
    Chan, Cato
    Shaffer, Jenny L.
    Kunz, Pamela L.
    Koong, Albert C.
    Chang, Daniel T.
    PANCREAS, 2014, 43 (05) : 777 - 783
  • [35] Differential expression of CD175 and CA19-9 in pancreatic adenocarcinoma
    Cheng, Jane J.
    Matsumoto, Yasuyuki
    Dombek, Gabrielle E.
    Stackhouse, Kathryn A.
    Ore, Ana Sofia
    Glickman, Jonathan N.
    Heimburg-Molinaro, Jamie
    Cummings, Richard D.
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [36] Utility of serum CA19-9 levels in the diagnosis of pancreatic ductal adenocarcinoma in an endoscopic ultrasound referral population
    Parikh D.A.
    Durbin-Johnson B.
    Urayama S.
    Journal of Gastrointestinal Cancer, 2014, 45 (1) : 74 - 79
  • [37] High preoperative serum CA19-9 level is predictive of poor prognosis for patients with colorectal liver oligometastases undergoing hepatic resection
    Lu, Zhenhai
    Peng, Jianhong
    Wang, Zhiqiang
    Pan, Zhizhong
    Yuan, Yunfei
    Wan, Desen
    Li, Binkui
    MEDICAL ONCOLOGY, 2016, 33 (11)
  • [38] Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer
    Liu, Jianqiang
    Gao, Jun
    Du, Yiqi
    Li, Zhaoshen
    Ren, Yan
    Gu, Junjun
    Wang, Xiaowei
    Gong, Yanfang
    Wang, Weiwei
    Kong, Xiangyu
    INTERNATIONAL JOURNAL OF CANCER, 2012, 131 (03) : 683 - 691
  • [39] Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma
    Michele Reni
    Umberto Peretti
    Silvia Zanon
    Marina Macchini
    Gianpaolo Balzano
    Elena Mazza
    Domenico Tamburrino
    Giulia Orsi
    Paolo Giorgio Arcidiacono
    Massimo Falconi
    Luca Gianni
    Cancer Chemotherapy and Pharmacology, 2020, 85 : 641 - 650
  • [40] Comparison of clinical usefulness of serum Ca125 and CA19-9 in pancreatic adenocarcinoma diagnosis: meta-analysis and systematic review of literature
    Skulimowski, Aleksander
    Durczynski, Adam
    Strzelczyk, Janusz
    Hogendorf, Piotr
    BIOMARKERS, 2021, 26 (04) : 287 - 295